Influence of topiramate on olanzapine-related adiposity in women: A random, double-blind, placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 25, Issue 3, 2005, Pages 211-217

  Nickel, Marius K ^a,b,d   Nickel, Cerstin ^a   Muehlbacher, Moritz ^b   Leiberich, Peter K ^c   Kaplan, Patrick ^b   Lahmann, Claas ^c   Tritt, Karin ^c   Krawczyk, Jakub ^b   Kettler, Christian ^a   Egger, Christoph ^b   Rother, Wolfhardt K ^a   Loew, Thomas H ^c  

^a Clinic for Psychosomatic Medicine   (Germany)

^b University Clinic for Psychiatry   (Austria)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d Inntalklinik ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BROMAZEPAM; CHLORPROTHIXENE; DIAZEPAM; FLUOXETINE; IMIPRAMINE; LEVOMEPROMAZINE; MIRTAZAPINE; OLANZAPINE; OXAZEPAM; PAROXETINE; PLACEBO; PROTHIPENDYL; REBOXETINE; TOPIRAMATE; TRIMIPRAMINE; VENLAFAXINE;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEALTH STATUS; HEALTH SURVEY; HUMAN; MAJOR DEPRESSION; OBESITY; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SELF REPORT; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; ANTI-OBESITY AGENTS; BENZODIAZEPINES; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; MENTAL DISORDERS; NEUROPSYCHOLOGICAL TESTS; STATISTICS, NONPARAMETRIC; WEIGHT GAIN; WEIGHT LOSS;

EID: 21044450810     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000162806.46453.38     Document Type: Article

References (44)

1. Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics [review]. J Clin Psychopharmacol. 1995;15(suppl 1):24-29.
2. Readler TJ, Schreiner A, Naber D, et al. Risperidone in the treatment of acute schizophrenia. J Clin Psychopharmacol. 2004;24(3):335-338.
3. Tandon R. Improvement without impairment: a review of clinical data for quetiapine in the treatment of schizophrenia. J Clin Psychopharmacol. 2003;23(suppl 1):15-20.
4. Kane JM. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. J Clin Psychiatry. 2003;64(suppl 19):19-25.
5. Carriere P, Bonhomme D, Lemperiere T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry. 2000;15:321-329.
6. Fleming K, Thyrum P, Yeh C, et al. Cognitive improvements in psychotic subjects treated with "Seroquel" (quetiapine fumarate): an exploratory study. J Clin Psychopharmacol. 2001;21(5):527-529.
7. Harvey PD. Ziprasidone and cognition: the evolving story. J Clin Psychiatry. 2003;64(suppl 19):33-39.
8. Rosen EH. Olanzapine and negative symptoms. J Clin Psychiatry. 1998;59(10):537-538.
9. Nickel M, Leiberich P, Mitterlehner F. Atypicaly neuroleptics in personality disorders. Psychodyn Psychother. 2003;2:25-32.
10. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry. 2000;61(suppl 3):16-21.
11. Costa e Silva JA, Alvarez N, Mazzotti G, et al. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol. 2001;21(4):375-381.
12. Ritsner M, Perelroyzen G, Ilan H, et al. Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol. 2004;24(3):245-254.
13. Kasper S. First-episode schizophrenia: the importance of early intervention and subjektive tolerability. J Clin Psychiatry. 1999;60(suppl 23):5-9.
14. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63:1121-1128.
15. Hellewell JS. Patients' subjective experiences of antipsychotics: clinical relevance. CNS Drugs. 2002;16(7):457-471.
16. Smith S. Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practice. J Clin Psychopharmacol. 2003;23(suppl 1):27-32.
17. Wetterling T, Mussigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol. 1999;19(4):316-321.
18. Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol. 2003;23(suppl 1):21-26.
19. Baptista T, Beaulieu S. Body weight gain, insulin, and leptin in olanzepine-treated patients. J Clin Psychiatry. 2001;62:902-904.
20. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62(suppl 7):22-31.
21. McIntyre RS, Mancini DA, Basile VS, et al. Antipsychotic-induced weight gain: bipolar disorder and leptin. J Clin Psychopharmacol. 2003;23(4):323-327.
22. Basile VS, Masellis M, McIntyre RS, et al. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry. 2001;62(suppl 23):45-66.
23. Bouchard RH, Demers MF, Simoneau I, et al. Atypical antipsychotics and cardiovascular risk in schizophrenic patients. J Clin Psychopharmacol. 2001;21(1):110-111.
24. Gianfrancesco F, White R, Wang RH, et al. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol. 2003;23(4):328-335.
25. Meltzer HY. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry. 2001;62(suppl 27):35-39.
26. Abu-Abid S, Szold A, Klausner J. Obes Cancer. 2002;33:73-86.
27. Haynes G, Dunnagan T. Comparing changes in health risk factors and medical costs over time. Am J Health Promot. 2002;17:112-121.
28. Pronk NP, Goodman MJ, O'Connor PJ, et al. Relationship between modifiable health risks and short-term health care charges. JAMA. 1999;282:2235-2239.
29. Pronk NP, Tan AW, O'Connor P. Obesity, fitness, willingness to communicate and health care costs. Med Sci Sports Exerc. 1999;31:1535-1543.
30. Werneke U, Taylor D, Sanders TA. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol. 2002;17:145-160.
31. Cavazzoni P, Tanaka Y, Roychowdhury SM, et al. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13:81-85.
32. Hilger E, Quiner S, Ginzel I, et al. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol. 2002;22:68-70.
33. Anghelescu I, Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain. J Clin Psychopharmacol. 2000;20:716-717.
34. White HS, Brown SD, Woodhead JH, et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997;28:167-179.
35. Anghelescu I, Klawe C, Szegedi A. Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior. J Clin Psychopharmacol. 2002;22(5):521-524.
36. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry. 2002;63:1045.
37. Husum H, Van Kammen D, Termeer E, et al. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology. 2003;28:1292-1299.
38. Nickel M, Nickel C, Mitterlehner F, et al. Treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004;65:1515-1519.
39. Muellner M. Evidence Based Medicine. Wien: Springer; 2002.
40. Bullinger M, Kirchberger I. Fragebogen zum Gesundheitszustand (SF-36). Goettingen: Hogrefe; 1998.
41. von Zerssen D. Befindlichkeitsskala (Bf-S). In: Collegium Internationale Psychiatriae Scalarum, ed. Internationale Skalen für Psychiatrie. Goettingen: Beltz; 1996.
42. Janke W, Debus G. Eigenschaftswörterliste (EWL-60-S). In: Collegium Internationale Psychiatriae Scalarum, ed. Internationale Skalen für Psychiatrie. Goettingen: Beltz; 1996.
43. Bozikas VP, Petrikis P, Kourtis A, et al. Treatment of acute mania with Topiramate in hospitalized patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1203-1206.
44. Nickel M, Nickel C, Leiberich P, et al. Psychosocial characteristics in persons who often change their psychotherapists. Wien Med Wochenschr. 2004;154:163-169.